The PennZone

  • Home
  • Non-profit
  • Books
  • Marketing
  • Entertainment
  • Business
  • Health
  • Music
  • Automotive

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
  • DayPass launches in ChatGPT and Claude
  • DayPass llega a ChatGPT y Claude
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Attorney Jason M. Sullivan Quoted in The Telegraph on Trump's $10 Billion BBC Lawsuit
  • Sherri Horsey Darden: A Visionary Woman Building a Legacy of Inspiration, Community, and Excellence
  • Sycamore Dove Releases "Loving Every Moment"
  • Hospital Direct Medical Equipment Company Seeing Growth in Used Refurbished Medical Equipment Sales
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Nashville

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • National Literacy and Workforce Readiness Crisis Sparks New Program Launching in Birmingham
  • New England Consulting Partners Celebrates 25 Years of Turnaround Management Solutions
  • RAS AP Consulting Releases Educational Resource to Help Organizations Prepare for IRS FIRE-to-IRIS Transition
  • York County Is an EPA Radon Zone 1. Here Is What Homeowners Should Know Before Testing
  • What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type
  • Roots, Rhythm & Joy Invites Neighbors to Find Community Through Music
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
  • Stand Strong Fencing of Hatfield Turns Every October Project Into a Cancer Donation
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
  • Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner
  • Heritage at Manalapan Announces Limited-Time Mortgage Rate Buydown on Select Quick Move-In Homes
  • Good Organics Now at Pop Up Grocer NYC With October 30 Sampling Event
  • KeysCaribbean Announces Temporarily Reduced Rates At Village at Hawks Cay Villas
  • Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
  • Electives Launches "Electives for Everyone," Making Live Expert-Led Learning Available to Every Employee
  • Tax Tops the List as Wealthy Brits Plan Their Exit, La Vida Survey Finds
  • "The Tree of Cinema" Installation Brought Film History and Its Audiences Together at TIFF 2026
  • Detroit Lawyer Steals $600,000 Settlement Meant to Protect Child
  • The Great Junk Hunt Makes Its Highly Anticipated Stop in Philadelphia (Oaks)!
  • Heritage at South Brunswick Announces Special Townhome Mortgage Rate Buydown

Popular on PennZone

  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers - 150
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh - 112
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
  • World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
  • Keystone Consulting Engineers Expands into Brodheadsville, Strengthening Regional Engineering
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026

Similar on PennZone

  • Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
  • Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
  • Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us